By Linda Avey in prweb.
Precise.ly, Inc. has been selected to be the patient portal in a $40 million, five-year NIH-funded, multi-center study focused on the study of chronic fatigue syndrome (ME/CFS). It represents the first major research support for a condition that affects millions of Americans.
SAN FRANCISCO, (CALIF.) (PRWEB) OCTOBER 09, 2017
Precise.ly, Inc. has been selected to be the patient portal in an NIH-funded, multi-center study focused on the study of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The funding, totaling over $40 million, extends over five years and represents the first major research support for a condition that affects millions of Americans.
The National Institutes of Health has awarded funding to three ME/CFS Collaborative Research Centers (CRCs) including the Bateman Horne Center, directed by Lucinda Bateman, M..D and Suzanne Vernon, Ph.D., The Jackson Laboratory, led by Derya Unutmaz, M.D., Columbia University and Cornell.
It’s predicted as many as 2.5 million Americans have ME/CFS, a debilitating disease characterized by extreme fatigue after exertion that is not relieved by rest, and other symptoms, including cognitive dysfunction, and muscle and joint pain.
“ME/CFS is unique to each person, from what caused their disease to the array of symptoms. Despite this we’ve put one ‘label’ on it. This has hindered our ability to diagnose and treat it effectively. We need patients to help us identify these unique characteristics of ME/CFS. Precise.ly puts patients at the center of this fundamental first step for a deeper understanding of this disease,” said Dr. Vernon.
To read the rest of this story, click on the link below: